When question about the recent share price rise this was part of the reply to asx
Quote
3. As previously announced the FDA mid-cycle review process is scheduled for completion in 1Q 2023. This is considered a significant milestone event, as it will provide written feedback from FDA if there are any significant review issues remaining for product approval. The Company is waiting to receive this communication from FDA.
end of quote
Bot Chart, page-6148
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $636.1M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 36.0¢ | 34.0¢ | $2.246M | 6.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 54114 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 80800 | 5 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |